Organogenesis Holdings Inc. (ORGO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Organogenesis Holdings Inc. (ORGO) trades at $2.46 with AI Score 38/100 (Grade D). Organogenesis Holdings Inc. is a regenerative medicine company focused on advanced wound care and surgical solutions. Market cap: $316M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 4, 2026Analyst Coverage for ORGO: ORGO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ORGO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ORGO: 2/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Organogenesis Holdings Inc. (ORGO) Healthcare & Pipeline Overview
Organogenesis Holdings Inc. develops and commercializes regenerative medicine solutions for advanced wound care and surgical applications. The company's diverse product portfolio, including bioengineered tissues and cellular therapies, addresses unmet needs in hospitals, wound care centers, and physician offices across the United States.
What Is the Investment Thesis for ORGO?
Organogenesis Holdings Inc. presents a notable research candidate within the regenerative medicine space. With a market capitalization of $316M and a P/E ratio of 8.81, the company demonstrates profitability and growth potential. A gross margin of 74.4% indicates strong pricing power and efficient operations. Key growth catalysts include the expansion of the company's product portfolio with pipeline products like PuraPly XT and PuraForce, and increasing adoption of regenerative medicine solutions in wound care and surgical applications. Potential risks include competition from established players and the regulatory approval process for new products.
Based on FMP financials and quantitative analysis
ORGO Key Highlights
- Market Cap of $316M indicates a mid-sized player in the regenerative medicine market.
- P/E Ratio of 8.81 suggests the company is potentially undervalued compared to its earnings.
- Profit Margin of 6.6% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 74.4% highlights the company's efficient production and pricing strategies.
- Beta of 1.48 indicates higher volatility compared to the market, potentially offering higher returns but also greater risk.
Who Are ORGO's Competitors?
ORGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CPHRF Cipher Pharmaceuticals Inc. | $11.62 | -0.53% | $295M | 63 |
| VREOF Vireo Growth Inc. | $9.75 | -0.61% | $373M | 62 |
| SIGA SIGA Technologies, Inc. | $3.15 | -7.08% | $226M | 75 |
| EMBC Embecta Corp. | $3.25 | +0.00% | $193M | 73 |
| AMPH Amphastar Pharmaceuticals, Inc. | $18.87 | -2.23% | $832M | 74 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| PCRX Pacira BioSciences, Inc. | $25.93 | +1.33% | $1.02B | 85 |
| CRON Cronos Group Inc. | $2.74 | -1.44% | $1.02B | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ORGO's Key Strengths?
- Diverse product portfolio in wound care and surgical solutions
- Proprietary bioengineered tissue technologies
- Established sales channels and customer relationships
- Strong gross margin indicating pricing power
What Are ORGO's Weaknesses?
- Reliance on a limited number of key products
- Exposure to regulatory risks and approval processes
- Competition from established players in the wound care market
- Potential for product liability claims
What Could Drive ORGO Stock Higher?
- Potential FDA approval of PuraPly XT and PuraPly MZ for expanded wound care applications.
- Increasing adoption of NuCel in orthopedic and neurosurgical procedures.
- Commercialization of PuraForce surgical matrix for soft tissue reinforcement.
- Expansion into international markets, such as Europe and Asia.
What Are the Key Risks for ORGO?
- Negative return on equity (-0.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the wound care market.
- Regulatory changes and approval delays for new products.
- Product liability claims related to regenerative medicine therapies.
- Economic downturn affecting healthcare spending.
What Are the Growth Opportunities for ORGO?
- Expansion of PuraPly Product Line: Organogenesis is developing PuraPly XT and PuraPly MZ to address a broader range of chronic and acute wounds. The chronic wound care market is estimated to reach $10 billion by 2028, driven by the rising incidence of diabetes and obesity. Successful commercialization of these products could significantly increase Organogenesis's market share and revenue within the next 2-3 years.
- Adoption of NuCel in Surgical Applications: NuCel, a dehydrated placental tissue, is used to support native healing in surgical procedures. The surgical and sports medicine market is experiencing growth due to advancements in minimally invasive techniques and increasing demand for regenerative solutions. Increased adoption of NuCel in orthopedic and neurosurgical applications could drive significant revenue growth over the next 3-5 years.
- Commercialization of PuraForce Surgical Matrix: PuraForce, a bioengineered porcine collagen surgical matrix, is designed for soft tissue reinforcement applications. The market for surgical matrices is growing due to the increasing number of complex surgical procedures and the demand for improved patient outcomes. Successful commercialization of PuraForce could generate substantial revenue within the next 3-4 years.
- Geographic Expansion: Organogenesis primarily operates in the United States. Expanding into international markets, such as Europe and Asia, could unlock significant growth opportunities. The global wound care market is projected to reach $22 billion by 2027, with Asia being the fastest-growing region. International expansion could contribute to revenue growth over the next 5 years.
- Strategic Partnerships and Acquisitions: Organogenesis can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborating with other companies in the regenerative medicine space could accelerate innovation and drive revenue growth. These partnerships could materialize within the next 1-2 years.
What Opportunities Does ORGO Have?
- Expansion into new geographic markets
- Development of innovative regenerative medicine therapies
- Strategic partnerships and acquisitions
- Increasing adoption of regenerative medicine in wound care and surgery
What Threats Does ORGO Face?
- Competition from established players and emerging companies
- Regulatory changes and approval delays
- Product liability claims
- Economic downturn affecting healthcare spending
What Are ORGO's Competitive Advantages?
- Proprietary bioengineered tissue technologies
- Established relationships with hospitals and wound care centers
- Strong brand recognition in the advanced wound care market
- Extensive product portfolio addressing diverse clinical needs
What Does ORGO Do?
Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis Holdings Inc. has evolved into a leading regenerative medicine company. The company focuses on developing, manufacturing, and commercializing innovative solutions for the advanced wound care, and surgical and sports medicine markets. Organogenesis's advanced wound care products include Affinity, Apligraf, Dermagraft, NuShield, PuraPly, and Novachor. These products utilize bioengineered tissues and cellular therapies to promote healing in chronic and acute wounds. The company's surgical and sports medicine products include NuCel, ReNu, FiberOS, and OCMP, which are designed to support tissue regeneration and bone repair in surgical applications. Organogenesis serves a diverse customer base, including hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices, through a direct sales force and independent agencies. The company's pipeline includes PuraPly XT, PuraPly MZ, PuraForce, and TransCyte, targeting expanded applications in wound care and surgical reinforcement.
What Products and Services Does ORGO Offer?
- Develops regenerative medicine solutions for wound care.
- Manufactures bioengineered tissues and cellular therapies.
- Commercializes advanced wound care products like Affinity, Apligraf, and Dermagraft.
- Offers surgical and sports medicine products such as NuCel and ReNu.
- Provides solutions for hospitals, wound care centers, and physician offices.
- Focuses on promoting healing and tissue regeneration.
How Does ORGO Make Money?
- Develops and manufactures regenerative medicine products.
- Sells products directly to hospitals, wound care centers, and physician offices.
- Utilizes a direct sales force and independent agencies for distribution.
- Generates revenue through product sales and licensing agreements.
What Industry Does ORGO Operate In?
Organogenesis Holdings Inc. operates in the growing regenerative medicine market, which is driven by the increasing prevalence of chronic wounds, surgical procedures, and sports-related injuries. The market is characterized by intense competition among established players and emerging companies developing innovative therapies. Organogenesis differentiates itself through its diverse product portfolio, proprietary technologies, and established sales channels. The company's focus on bioengineered tissues and cellular therapies positions it to capitalize on the growing demand for advanced wound care and surgical solutions.
Who Are ORGO's Key Customers?
- Hospitals
- Wound care centers
- Government facilities
- Ambulatory service centers
- Physician offices
FY2026 estForward Outlook
Wall Street analysts project Organogenesis Holdings Inc. revenue of about $282.9M for fiscal 2026, with EPS near $-0.82.
ORGO Valuation & Market Position
With a $316M market cap, Organogenesis Holdings Inc. sits in the small-cap segment of the market. Relative to its peer group, ORGO's quantitative score of 38/100 is below the peer average of 69/100.
ROE -0%Key Financial Metrics
Return on equity for Organogenesis Holdings Inc. stands at -0.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Organogenesis Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.68 places it in the grey zone, a middle ground that warrants monitoring.
Company Profile
Organogenesis Holdings Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Canton, US. The company is led by CEO Gary S. Gillheeney. ORGO has traded publicly since 2017.
ORGO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio in wound care and surgical solutions
- Proprietary bioengineered tissue technologies
- Established sales channels and customer relationships
- Strong gross margin indicating pricing power
Bear Case
- Reliance on a limited number of key products
- Exposure to regulatory risks and approval processes
- Competition from established players in the wound care market
- Potential for product liability claims
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ORGO Latest News
-
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
benzinga · Jul 21, 2026
-
Earnings Scheduled For February 26, 2026
benzinga · Feb 26, 2026
ORGO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORGO.
Price Targets
Wall Street price target analysis for ORGO.
ORGO MoonshotScore
What does this score mean?
The MoonshotScore rates ORGO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gary S. Gillheeney
CEO
Gary S. Gillheeney serves as the CEO of Organogenesis Holdings Inc., leading the company's strategic direction and growth initiatives. His background includes extensive experience in the healthcare industry, with a focus on regenerative medicine and wound care. He has held various leadership positions in sales, marketing, and operations, demonstrating a comprehensive understanding of the healthcare market. His expertise spans product development, commercialization, and market access strategies.
Track Record: Under Gary S. Gillheeney's leadership, Organogenesis Holdings Inc. has achieved significant milestones, including the expansion of its product portfolio, increased market share in the advanced wound care market, and successful commercialization of innovative regenerative medicine therapies. He has overseen the company's growth strategy, driving revenue growth and profitability. His strategic decisions have positioned Organogenesis as a leader in the regenerative medicine industry.
What Investors Ask About Organogenesis Holdings Inc. (ORGO) — Healthcare
What does the AI Score mean for ORGO?
ORGO holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Organogenesis Holdings Inc. is a regenerative medicine company focused on advanced wound care and surgical solutions. Their products include a range of bioengineered tissues and cellular therapies.
What does Organogenesis Holdings Inc. do?
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical applications. Their product portfolio includes bioengineered tissues and cellular therapies designed to promote healing and tissue regeneration. The company serves hospitals, wound care centers, and physician offices through a direct sales force and independent agencies, focusing on addressing unmet needs in the healthcare market with innovative regenerative medicine solutions.
What do analysts say about ORGO stock?
Analyst consensus on ORGO stock reflects a mixed outlook, with some analysts highlighting the company's growth potential in the regenerative medicine market, while others express concerns about competition and regulatory risks. Key valuation metrics, such as the P/E ratio and gross margin, are closely monitored. Growth considerations include the successful commercialization of pipeline products and expansion into new geographic markets.
What are the main risks for ORGO?
The main risks for Organogenesis Holdings Inc. include competition from established players and emerging companies in the wound care market, regulatory changes and approval delays for new products, and potential product liability claims related to regenerative medicine therapies. Economic downturns affecting healthcare spending could also pose a risk. These factors could impact the company's revenue growth, profitability, and market share.
What are the key factors to evaluate for ORGO?
Organogenesis Holdings Inc. (ORGO) holds an AI score of 38/100 (low). Not financial advice.
How frequently does ORGO data refresh on this page?
ORGO's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ORGO's recent stock price performance?
Organogenesis Holdings Inc. (ORGO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in wound care and surgical solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORGO overvalued or undervalued right now?
Organogenesis Holdings Inc. (ORGO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORGO before investing?
Before investing in Organogenesis Holdings Inc. (ORGO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Analyst opinions and financial metrics are for informational purposes only and should not be considered investment advice.